Meeting
2012 ASCO Annual Meeting
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
Authors
George Somlo
City of Hope, Duarte, CA
George Somlo , Joseph A. Sparano , Tessa Cigler , Gini F. Fleming , Thehang H. Luu , Arti Hurria , Joanne E. Mortimer , Paul Henry Frankel , Helen K. Chew , Rita Nanda , Cynthia X. Ma , Alice P. Chen , Agustin Garcia , Linda T. Vahdat , David R. Gandara , Jeffrey N. Weitzel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01149083
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1010)
DOI
10.1200/jco.2012.30.15_suppl.1010
Abstract #
1010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.
First Author: George Somlo
Poster
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
First Author: Deborah Kay Armstrong
Poster
2015 ASCO Annual Meeting
![Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i>- or <i>BRCA2</i>- (<i>BRCA</i>)-associated metastatic breast cancer (MBC).](https://d201v5jt9ylckg.cloudfront.net/156/10671/112102/112102_poster_pv.jpg)
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
First Author: George Somlo
Poster
2015 Genitourinary Cancers Symposium
Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Shalu Pahuja